FDA Recalls Triptropin Plus Injectable Due to Sterility Assurance Concerns
Beacon Hill Medical Pharmacy is recalling Triptropin Plus Injectable because FDA inspections raised concerns about quality control procedures that impacted sterility assurance.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of assurance of sterility in an injectable medication, which poses a significant risk of serious health consequences such as infection.
Plain-English summary
The U.S. Food and Drug Administration (FDA) has issued a Class II recall for Triptropin Plus Injectable, compounded by Beacon Hill Medical Pharmacy, P.C. (dba Rxtra Solutions) in Southfield, Michigan. The recall covers all configurations of the sterile, prescription-only injectable intended for intravenous and subcutaneous use.
The recall was initiated due to a lack of assurance of sterility. FDA inspectional findings identified concerns associated with quality control procedures that impacted the sterility assurance of the product. The affected lots were distributed nationwide in the United States.
Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or pharmacist for further instructions. The specific lot codes associated with this recall are listed in the official FDA documentation.
The recalled product
- Product
- TRIPTROPIN PLUS INJECTABLE, all configurations, FOR INTRAVENO AND SQ USE ONLY, STERILE, RX ONLY, Compounded by Beacon Hill Medical Pharmacy PC, dba Rxtra Solutions, Southfield, MI
- Manufacturer
- Beacon Hill Medical Pharmacy, P.C.
- Category
- Drug — Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (13)
- 07022013@37
- 01152013@32
- 03012013@22
- 03062013@15
- 03122013@14
- 04102013@4
- 04242013@14
- 04302013@2
- 05242013@9
- 06122013@26
- 06122013@20
- 07112013@16
- 07232013@2
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 86 recalled by Beacon Hill Medical Pharmacy, P.C. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · Beacon Hill Medical Pharmacy, P.C.
See all →- SevereBeacon Hill Medical Pharmacy Recalls B-12 Injectable Due to Sterility Concerns
FDA (Drugs) · 2013-09-18
- HighBeacon Hill Medical Pharmacy Recalls Sermorelin Acetate Injectable Due to Sterility Concerns
FDA (Drugs) · 2013-09-18
- SevereBeacon Hill Medical Pharmacy Recalls Potassium Chloride Injectable Due to Sterility Concerns
FDA (Drugs) · 2013-09-18
- SevereBeacon Hill Medical Pharmacy Recalls Alprostadil Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-18
- SevereBeacon Hill Medical Pharmacy Recalls Multitrace-5 Injectable Due to Sterility Concerns
FDA (Drugs) · 2013-09-18
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29